The medication Imbruvica® (ibrutinib) from AbbVie offers well-researched benefits for several blood cancers. Last month, my blog Potential New Medication for Lymphoma, shared how this medication was approved by the FDA in 2013 for mantle cell lymphoma, with approvals for chronic lymphocytic leukemia and Waldenstrom’s macroglobulinemia coming in the following years. Now Imbruvica is undergoing an accelerated approval process for another form of lymphoma: marginal zone lymphoma.
Carrying around extra pounds presents clear health risks. In addition to the well-known connections between obesity and hypertension, high cholesterol, and diabetes, excessive weight also increases the risk of at least 11 types of cancer. Cancer is currently a leading cause of death worldwide, yet worryingly the amount of people who are obese has more than doubled since the 1970s.
Breast cancer remains the most common cancer in women worldwide, which means that many women will undergo treatment for this disease in their life. The commonly used chemotherapy for treating breast cancer is well-known for the side effect of hair loss. Research shows that cooling the scalp can help reduce the hair loss induced by chemotherapy.
Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, particularly when it comes to direct-acting antiviral medications. This included various drug approvals and access improvements for hepatitis C medications, including Daklinza, Epclusa, Sovaldi/velpatasvir, Viekira, and Zepatier. As we make our way deeper into 2017, this breakneck speed of new treatment options for hepatitis C is not expected to continue; however, there is still a lot of interesting activity underway in the world of hepatitis C.
Many of your patients will likely need to be screened for hepatitis C, which means that they will have many questions during the testing process. This blog geared to patient education can help your patients understand each step of what can be a stressful time in their lives.
The medication Imbruvica® (ibrutinib) from AbbVie first gained FDA approval in 2013 for treating mantle cell lymphoma, then in 2014 the approval was expanded to include chronic lymphocytic leukemia. The next year, 2015, Waldenstrom’s macroglobulinemia was added to the FDA approvals for this medication. Now, in 2017, Imbruvica has been granted an accelerated approval as a treatment for another form of lymphoma: marginal zone lymphoma (MZL).
Finding an activity that one can do regularly – whether that’s walking, playing basketball, cycling, or anything else that raises heart rates and moves big muscle groups – brings health benefits in a variety of ways. Lowering the risk of cancer is one such benefit, particularly when it comes to breast and colon cancers (as well as prostate, lung, and endometrial cancer risk).
The initial infection with hepatitis C, the time of acute infection when some people experience flu-like symptoms, can result in weight loss due to poor appetite. For the most part, however, those infected with the hepatitis C virus (HCV) experience no symptoms. This lack of symptoms is why hepatitis C is known as the silent epidemic; it’s also why so many people can be infected for years or even decades without knowing their disease status.
Today’s hepatitis C medications offer extremely high cure rates. In fact, the few cases of a previously treated patient later testing positive for hepatitis C has some patients wondering “did I relapse or could I have been reinfected?”
Inflammatory bowel disease – which includes both Crohn’s disease and ulcerative colitis – affects 1.6 million Americans, a number that continues to rise. Each year, the U.S. sees 70,000 new cases diagnosed. Although a cure remains elusive, these chronic and life-long diseases can be treated with a variety of treatment options.